Tag: #Global Trends

On January 8, 2026, the U.S. Food and Drug Administration (FDA) granted approval for a new 2-gram (g) formulation of... Read more

New data from the phase 3 Herizon-Gea-01 clinical trial signals a potential paradigm shift in the first-line treatment of HER2-positive... Read more

The German chemical and pharmaceutical giant Bayer has filed separate lawsuits against Moderna, Johnson & Johnson (J&J), and the Pfizer-BioNTech... Read more

Clarivate’s annual "Drugs to Watch 2026" report has identified 11 potential blockbusters, with Eli Lilly’s cardiometabolic therapies taking center stage.... Read more

The pharmaceutical giant Amgen has finalized an agreement to purchase Dark Blue Therapeutics, a UK-based biotechnology firm. The total valuation... Read more

Global pharmaceutical leader Pfizer has entered into a multi-year strategic collaboration with Cartography Biosciences to identify novel tumor-selective antigens. The... Read more

For the second time, Eli Lilly has joined forces with Boston-based Nimbus Therapeutics to advance a potential weight-loss therapy. The... Read more

On January 6, 2026, Health Canada granted authorization to Arrowhead Pharmaceuticals for Redemplo (plozasiran). This milestone marks the first small... Read more

On January 6, 2026, BostonGene, a developer of foundational AI models for tumor and immune biology, announced a strategic collaboration... Read more